Serono's Serostim: Changing Criteria for European Biologics Approval
Executive Summary
Serono's appealing the European regulator's negative opinion on AIDS-wasting treatment Serostim reflects more than the product's importance to the Swiss group. The rift highlights confusion surrounding Europe's biologics approval process and reinforces fears that cost-conscious Europe is not rewarding innovation.